NCT00310180 2026-03-18
TAILORx
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
65 trialsNCT01674140 2026-02-10
e3
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT00066690 2026-02-06
SOFT
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT02115282 2025-12-18
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06086340 2025-11-18
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Pfizer
Completed
NCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
NCT02007512 2025-09-02
Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Pfizer
Phase 2 Completed
NCT04975308 2025-07-11
EMBER-3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT00253422 2025-06-04
SoFEA
Institute of Cancer Research, United Kingdom
Phase 3 Completed
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03219476 2025-04-29
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT00265759 2025-04-23
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT02028507 2024-09-25
PEARL
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT04129216 2024-05-07
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
Johns Hopkins University
Phase 2 Completed
NCT02648477 2024-03-19
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT01814397 2024-02-07
Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
University of Michigan Rogel Cancer Center
Completed
NCT03312738 2024-01-23
BOLERO-5
Novartis
Phase 2 Completed
NCT02258451 2023-11-24
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
Phase 2 Completed
NCT00066573 2023-08-25
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00083174 2023-08-25
ExCel
Canadian Cancer Trials Group
Phase 3 Completed
NCT02598557 2023-08-22
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01698918 2023-05-03
BOLERO-4
Novartis
Phase 2 Completed
NCT02049957 2023-02-08
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
Calithera Biosciences, Inc
Phase 2 Completed
NCT03874325 2022-05-31
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01176916 2021-10-27
AromasinĀ® Interventional Study Of Early Invasive Breast Cancer Patients In China
Pfizer
Phase 4 Completed
NCT01783444 2021-02-26
BOLERO-6
Novartis
Phase 2 Completed
NCT00810797 2020-10-19
Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00905021 2020-07-24
EXTENT
Baylor Breast Care Center
Phase 1/2 Terminated
NCT01627067 2020-06-19
Exemestane-RAD001-Metformin
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03176238 2020-04-07
EVEREXES
Novartis
Phase 3 Completed
NCT02291913 2020-02-17
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01720602 2020-01-07
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
University of Washington
Phase NA Completed
NCT01153672 2019-09-06
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
University of Washington
Phase NA Completed
NCT01743560 2019-07-18
4EVERUK
Novartis
Phase 4 Completed
NCT01597193 2019-05-08
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Pfizer
Phase 1 Completed
NCT01381874 2019-04-11
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Janssen Research & Development, LLC
Phase 2 Completed
NCT01605396 2019-03-25
MK-8669-064
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01385280 2018-10-17
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
University of Arizona
Phase NA Completed
NCT00201864 2018-07-26
Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00728949 2018-06-06
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01484041 2018-02-09
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
Georgetown University
Phase 1/2 Terminated
NCT00194792 2017-07-11
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
University of Washington
Phase 2 Terminated
NCT00863655 2017-05-02
BOLERO-2
Novartis
Phase 3 Completed
NCT00941330 2017-04-10
Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Emory University
Phase 2 Completed
NCT00659373 2016-07-25
Co-SOFT
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT01896050 2016-06-28
LOGRIBMET
University of Michigan Rogel Cancer Center
Completed
NCT00073073 2016-05-17
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
Georgetown University
Phase 2 Completed
NCT01151046 2016-05-12
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
Merrimack Pharmaceuticals
Phase 2 Completed